已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Discovery and preclinical development of LY3473329, a potent small molecule inhibitor of lipoprotein(a) formation

载脂蛋白B 脂蛋白(a) 脂蛋白 家族性高胆固醇血症 体外 小分子 生物化学 医学 胆固醇 化学
作者
L Michael,Carlos A. Perez,Celia Lafuente,Ginés Sanz,Julián Priego,Amparo Escribano,Luis Calle,Juan F. Espinosa,M Sauder,Birgit T. Priest,Alexander Schultze,Amanda K. Nosie,H Zhang,Stephen J. Nicholls,Néstor Fabián Díaz
出处
期刊:European Heart Journal [Oxford University Press]
卷期号:44 (Supplement_2)
标识
DOI:10.1093/eurheartj/ehad655.2797
摘要

Abstract Background Lipoprotein(a) [Lp(a)] is a lipoprotein particle consisting of a low-density lipoprotein (LDL) particle and apolipoprotein(a) [apo(a)]. Lp(a) is a causal risk factor for cardiovascular disease. The formation of Lp(a) requires an initial interaction of apo(a) Kringle IV Domains 7 and 8 (KIV7, KIV8) with apoB-100 on LDL, followed by formation of a disulfide bond between apo(a) and apoB-100. Blocking the initial apo(a)-apoB interaction is a viable therapeutic approach to reduce circulating levels of Lp(a). The apo(a) protein is encoded by the LPA gene that arose from the plasminogen gene through an evolutionary gene duplication event. Because of sequence conservation between apo(a) and plasminogen, compound selectivity for apo(a) is imperative for clinical development. Purpose We report the discovery and preclinical characterization of LY3473329, a novel selective small molecule inhibitor of Lp(a) formation. Methods Computational and synthetic chemistry approaches coupled with multiple biochemical and biophysical assays were used to create apo(a) KIV7,8 binders. Chemical optimization led to molecules with potent inhibition of in vitro Lp(a) formation. Both apo(a) and plasminogen binding assays were conducted to evaluate compound selectivity. The potential for LY3473329 to lower steady state Lp(a) levels was assessed in human Lp(a) transgenic mice and in cynomolgus monkeys, and its effect on plasminogen activity was assessed in rat and monkey. Results Computational modeling, synthetic chemistry and small molecule library screens identified compounds that bind apo(a) KIV7 and KIV8 domains, and subsequent chemical optimization yielded compounds with sub-micromolar Lp(a) inhibition potency. Exploration of compound multivalency created inhibitors with sub-nanomolar potency, including LY3473329. LY3473329 engages multiple apo(a) KIV motifs, allowing it to potently inhibit Lp(a) formation in vitro. Oral doses of LY3473329 given to human Lp(a) transgenic mice and cynomolgus monkeys caused dose-dependent decreases in plasma Lp(a). The key binding motif for LY3473329 is shared by two KIV domains in rat and monkey plasminogen, but only one KIV domain in human plasminogen. LY3473329 was non-selective for rat and monkey plasminogen, but showed ∼ 50-fold selectivity for human plasminogen in in vitro binding assays. In cynomolgus monkeys and rats, LY3473329 significantly reduced plasminogen activity levels without adverse effects. Given its selectivity against human plasminogen, LY3473329 is expected to lower Lp(a) in human without affecting plasminogen. LY3473329 has been evaluated in a human Phase 1 study and is currently in Phase 2 clinical development. Conclusions LY3473329 is a potent and selective small molecule inhibitor of Lp(a) formation and is the only orally administered Lp(a) investigational therapeutic in clinical development.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
左手树完成签到,获得积分10
1秒前
苏书白应助火星上牛青采纳,获得10
3秒前
3秒前
5秒前
FashionBoy应助YoYo采纳,获得10
6秒前
成就发夹完成签到,获得积分10
6秒前
8秒前
9秒前
9秒前
耍酷大炮发布了新的文献求助10
9秒前
忧心的雯发布了新的文献求助10
9秒前
10秒前
隐形曼青应助DamonChen采纳,获得10
12秒前
乔达摩完成签到 ,获得积分10
12秒前
13秒前
J11发布了新的文献求助10
14秒前
活泼千雁发布了新的文献求助10
15秒前
cxzydhcg发布了新的文献求助20
17秒前
舒适新梅发布了新的文献求助10
19秒前
李健的小迷弟应助J11采纳,获得10
19秒前
蝴蝶变成毛毛虫完成签到,获得积分10
19秒前
有丶神完成签到 ,获得积分10
20秒前
22秒前
22秒前
从容芮应助信仰xy采纳,获得50
24秒前
深情安青应助枝与采纳,获得10
25秒前
25秒前
子车茗应助忧心的雯采纳,获得10
27秒前
cc发布了新的文献求助10
28秒前
Bressanone发布了新的文献求助10
29秒前
30秒前
金皮卡发布了新的文献求助20
30秒前
30秒前
蓝愿发布了新的文献求助10
30秒前
小熊完成签到,获得积分10
31秒前
科研通AI2S应助科研通管家采纳,获得10
31秒前
32秒前
Owen应助科研通管家采纳,获得10
32秒前
Akim应助科研通管家采纳,获得10
32秒前
领导范儿应助科研通管家采纳,获得10
32秒前
高分求助中
Evolution 10000
Sustainability in Tides Chemistry 2800
юрские динозавры восточного забайкалья 800
Diagnostic immunohistochemistry : theranostic and genomic applications 6th Edition 500
Chen Hansheng: China’s Last Romantic Revolutionary 500
China's Relations With Japan 1945-83: The Role of Liao Chengzhi 400
Classics in Total Synthesis IV 400
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3150321
求助须知:如何正确求助?哪些是违规求助? 2801489
关于积分的说明 7844908
捐赠科研通 2458975
什么是DOI,文献DOI怎么找? 1308883
科研通“疑难数据库(出版商)”最低求助积分说明 628582
版权声明 601727